Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.
about
Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patientsA risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapyLiver disease, HIV and aging.Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.The role of toxicity-related regimen changes in the development of antiretroviral resistanceTenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database.Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medicationsRisk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In BotswanaMetabolic complications and treatment of perinatally HIV-infected children and adolescents.Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital.Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.A review of the toxicity of HIV medications.Treatment of HIV infection: Swedish recommendations 2009.The role of serum lactate in the acute care setting.Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction.Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.Dolutegravir/rilpivirine for the treatment of HIV-1 infection
P2860
Q26770753-FEE8BA6F-BEDC-4D46-B69D-5882536510D9Q28477707-32F1AF75-39E7-4C0F-ACBF-AE4060C0CAEFQ33810577-9179E974-E636-419A-BF07-63B786DC2385Q34209648-73BDC251-05F3-4D26-A1E2-C4E33E22DE40Q34431819-9E7FD6B6-F826-41B3-90E0-34BCBF0E5DABQ34472398-CD572C0C-67B8-4E0A-A8E1-21B3CC16E0B0Q35330053-7CD38184-F422-4EE7-AC95-E15B9E39DC36Q35534418-12B2BAB4-1583-412D-987F-539763EA5C7DQ35622844-CE309FE7-2E25-44B5-B023-933ACA6B65ADQ36102516-7482B1C7-C937-4402-B40E-1E05AA4F559CQ36158019-D61CE77A-5B98-4185-91AE-C422BD75A79DQ36329990-92E1D09A-1DEE-4E58-B119-811D3AC0AFD1Q36952291-BC287C90-A804-4853-AD81-CEF7DCBCAF8BQ37123310-22D6A36E-9FF1-4141-B341-0C981100C041Q37506855-A1330056-608E-438B-9DB3-9B5D11F3EF87Q37633495-3DD6136F-E4AB-4E70-B907-E50EF7A9BD28Q37634509-54BD47BC-B1F8-4B3B-B929-B35198B38798Q37771798-AAF8A744-6FB8-4AA1-8DDE-5F89785E83A4Q37784777-C5824545-97C0-43D2-B234-B8437267FF63Q37935116-F2468644-6834-4135-A04F-F226DE270B3EQ38111430-821B4B55-516F-4D75-90A0-6D0F97E7B1F9Q38805500-CA157366-FBAE-41A8-AF25-78D9BC6EF4D4Q42246328-9AF19F31-2DEB-4088-974E-2CE7281BEBC6Q51460886-C10297E1-2729-443D-8D3B-6D6614DB360CQ52374199-4B569155-3BB0-49C1-BBEE-192BB69CEC14Q59135153-6D99D909-0A6F-4E46-B7BA-72F1E1290AEC
P2860
Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@en
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@nl
type
label
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@en
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@nl
prefLabel
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@en
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@nl
P1433
P1476
Risk factors for lactic acidos ...... sed to antiretroviral therapy.
@en
P2093
Lactic Acidosis International Study Group
P304
P356
10.1097/QAD.0B013E3282F08CDC
P407
P577
2007-11-01T00:00:00Z